Literature DB >> 31780460

RESISTing the Need to Quantify: Putting Qualitative FDG-PET/CT Tumor Response Assessment Criteria into Daily Practice.

J G Peacock1, C T Christensen2, K P Banks3,4.   

Abstract

Tumor response assessments are essential to evaluate cancer treatment efficacy and prognosticate survival in patients with cancer. Response criteria have evolved over multiple decades, including many imaging modalities and measurement schema. Advances in FDG-PET/CT have led to tumor response criteria that harness the power of metabolic imaging. Qualitative PET/CT assessment schema are easy to apply clinically, are reproducible, and yield good prognostic results. We present 3 such criteria, namely, the Lugano classification for lymphoma, the Hopkins criteria, and the Neck Imaging Reporting and Data Systems criteria for head and neck cancers. When comparing baseline PET/CTs with interim or end-of-treatment PET/CTs, radiologists can classify the tumor response as complete metabolic response, partial metabolic response, no metabolic response, or progressive disease, which has important implications in directing further cancer management and long-term patient prognosis. The purpose of this article is to review the progression of tumor response assessments from CT- and PET/CT-based quantitative and semi-quantitative systems to PET/CT-based qualitative systems; introduce the classification schema for these systems; and describe how to use these rapid, powerful, and qualitative PET/CT-based systems in daily practice through illustrative cases.
© 2019 by American Journal of Neuroradiology.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31780460      PMCID: PMC6975356          DOI: 10.3174/ajnr.A6294

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   4.966


  55 in total

1.  18F-FDG PET/CT for Prognostic Stratification of Patients With Extranodal Natural Killer/T-Cell Lymphoma.

Authors:  Chunxia Qin; Shirui Yang; Xun Sun; Xiaotian Xia; Chunyan Li; Xiaoli Lan
Journal:  Clin Nucl Med       Date:  2019-03       Impact factor: 7.794

2.  Risk stratification of diffuse large B-cell lymphoma with interim PET-CT based on different cutoff Deauville scores.

Authors:  Jihyun Kim; Yoo Sung Song; Jong Seok Lee; Won Woo Lee; Sang Eun Kim
Journal:  Leuk Lymphoma       Date:  2017-06-20

3.  ACR Neck Imaging Reporting and Data Systems (NI-RADS): A White Paper of the ACR NI-RADS Committee.

Authors:  Ashley H Aiken; Tanya J Rath; Yoshimi Anzai; Barton F Branstetter; Jenny K Hoang; Richard H Wiggins; Amy F Juliano; Christine Glastonbury; C Douglas Phillips; Richard Brown; Patricia A Hudgins
Journal:  J Am Coll Radiol       Date:  2018-07-06       Impact factor: 5.532

4.  Metabolic behavior and prognostic value of early and end of treatment 18F-FDG PET/CT in adult Burkitt's lymphoma: the role of Deauville and IHP criteria.

Authors:  Domenico Albano; Giovanni Bosio; Alessandro Re; Chiara Pagani; Raffaele Giubbini; Francesco Bertagna
Journal:  Leuk Lymphoma       Date:  2018-07-03

5.  Head and neck PET/CT therapy response interpretation criteria (Hopkins criteria) - external validation study.

Authors:  Ayse Tuba Kendi; David Brandon; Jeffrey Switchenko; Jeffery Trad Wadsworth; Mark W El-Deiry; Nabil F Saba; David M Schuster; Rathan M Subramaniam
Journal:  Am J Nucl Med Mol Imaging       Date:  2017-09-01

Review 6.  Molecular Imaging and Precision Medicine: PET/Computed Tomography and Therapy Response Assessment in Oncology.

Authors:  Sara Sheikhbahaei; Esther Mena; Puskar Pattanayak; Mehdi Taghipour; Lilja B Solnes; Rathan M Subramaniam
Journal:  PET Clin       Date:  2016-10-05

7.  Accuracy of 18F-FDG PET/CT in Predicting Residual Disease After Neoadjuvant Chemoradiotherapy for Esophageal Cancer.

Authors:  Maria J Valkema; Bo Jan Noordman; Bas P L Wijnhoven; Manon C W Spaander; Katharina Biermann; Sjoerd M Lagarde; Roel J Bennink; Wendy M J Schreurs; Mark J Roef; Monique G G Hobbelink; Marcel J R Janssen; Laura H Graven; J Jan B van Lanschot; Roelf Valkema
Journal:  J Nucl Med       Date:  2019-03-15       Impact factor: 10.057

8.  FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma.

Authors:  N G Mikhaeel; M Hutchings; P A Fields; M J O'Doherty; A R Timothy
Journal:  Ann Oncol       Date:  2005-06-24       Impact factor: 32.976

9.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

Authors:  E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij
Journal:  Eur J Cancer       Date:  2009-01       Impact factor: 9.162

10.  Head and neck PET/CT: therapy response interpretation criteria (Hopkins Criteria)-interreader reliability, accuracy, and survival outcomes.

Authors:  Charles Marcus; Anthony Ciarallo; Abdel K Tahari; Esther Mena; Wayne Koch; Richard L Wahl; Ana P Kiess; Hyunseok Kang; Rathan M Subramaniam
Journal:  J Nucl Med       Date:  2014-06-19       Impact factor: 10.057

View more
  2 in total

1.  Performance of NI-RADS on CECT Alone to Predict Recurrent Head and Neck Squamous Cell Carcinoma after Chemoradiotherapy: Added Value of RECIST 1.1.

Authors:  Ishan Kumar; Syed O Reza; Sunil Choudhary; Ram C Shukla; Nilesh Mani; Ashish Verma
Journal:  Indian J Radiol Imaging       Date:  2022-07-30

2.  Positron Emission Tomographic Imaging of Tumor Cell Death Using Zirconium-89-Labeled APOMAB® Following Cisplatin Chemotherapy in Lung and Ovarian Cancer Xenograft Models.

Authors:  Vasilios Liapis; William Tieu; Nicole L Wittwer; Tessa Gargett; Andreas Evdokiou; Prab Takhar; Stacey E Rudd; Paul S Donnelly; Michael P Brown; Alexander H Staudacher
Journal:  Mol Imaging Biol       Date:  2021-07-06       Impact factor: 3.488

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.